Association of the ABCB1 3435C > T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists

Babaoglu M., Bayar B., Aynacioglu A., Kerb R., Abali H., Celik I., ...More

CLINICAL PHARMACOLOGY & THERAPEUTICS, vol.78, no.6, pp.619-626, 2005 (SCI-Expanded) identifier identifier identifier


Background: Resistance to antiemetic treatment with 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists is still a major problem resulting in patient discomfort and poor compliance to chemotherapy. We hypothesized that clinical resistance to 5-HT3 antagonists is associated with the single-nucleotide polymorphism (3435C > T) in the gene that codes for the drug efflux transporter adenosine triphosphate-binding cassette subfamily B member 1 (A-BCB1).